Mir Asghar, MD
Rheumatology · Howell, MINPI 1194752543
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,484 of the $4,451 with a category attached, or 78.3%. 15 manufacturers reported payments, led by AbbVie at 30.5% of the total. 2025 is the largest year on record at $2,880, more than ten times the $27 reported in 2021.
Across 174 payments — averaging $25.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Amgen$490
- AstraZeneca$429
- GSK$262
- UCB, Inc.$209
- plus $409 from 9 others
Across 5 payments — averaging $4869.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$24K
What the payments were for
- Travel & lodging$96722%
- Food & beverage$3,48478%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 73 | $1,360 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $1,292 |
| Amgen(2 entities) | 34 | $490 |
| AstraZeneca | 19 | $429 |
| GSK | 10 | $262 |
| UCB, Inc. | 7 | $209 |
| Sanofi | 5 | $97 |
| Novartis | 3 | $87 |
| ANI Pharmaceuticals, Inc. | 3 | $63 |
| Mallinckrodt Hospital Products Inc. | 3 | $47 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $29 |
| Aurinia Pharma U.S., Inc. | 1 | $28 |
| Pfizer | 1 | $21 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Exact Sciences | 1 | $17 |
How this compares
$4,451 in reported general payments places this provider in the 60th percentile of 195 rheumatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 70 | $496,534 |
| Humira PenAdalimumab | 32 | $358,946 |
| Humira(Cf) PenAdalimumab | 25 | $240,083 |
| RinvoqUpadacitinib | 21 | $129,321 |
| KevzaraSarilumab | 17 | $74,293 |
| EliquisApixaban | 22 | $15,162 |
| Hydroxychloroquine Sulfate | 206 | $10,613 |
| FarxigaDapagliflozin Propanediol | 14 | $7,192 |
| Leflunomide | 117 | $5,642 |
| Prednisone | 472 | $3,845 |
| MethotrexateMethotrexate Sodium | 182 | $3,782 |
| Mycophenolate Mofetil | 30 | $2,038 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 66 | $1,472 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 135 | $1,454 |
| Colchicine | 24 | $1,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $1,360 | $129,32121 claims |
| SanofiKevzara | $97 | $74,29317 claims |
| PfizerEliquis | $21 | $15,16222 claims |
| AstraZenecaFarxiga | $429 | $7,19214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 195 rheumatology providers in Michigan.
Other rheumatology in Howell
- Amar MajjhooSaint Clair Shores$1.8M
- Andrew SulichSaint Clair Shores$1.7M
- Dinesh KhannaAnn Arbor$1.2M
- Roman CzubatyjRochester Hills$764K
- Delfin SantosRochester$242K
- Allan MortonWarren$229K
- Elena SchiopuAnn Arbor$180K
- Alireza MeysamiNovi$170K
- Fazleomar MahmoodChelsea$167K
- Barakat ThabetGrand Rapids$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.